GlassScriptPhysician profile
Joseph E Albanese
NPI 1417160086
$3,894.58
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $590 · 2021: $388 · 2022: $143 · 2023: $535 · 2024: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $966.55 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $543.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.56 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $398.46 | 2019-2023 | Verquvo |
| Novo Nordisk INC | $186.67 | 2020-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $167.27 | 2020-2024 | Veozah |
| Lilly USA, LLC | $145.03 | 2019-2023 | Jardiance |
| Pfizer INC. | $138.00 | 2019-2023 | |
| Axsome Therapeutics, INC. | $135.57 | 2024 | Auvelity, Sunosi |
| Actelion Pharmaceuticals US, INC. | $120.81 | 2020 | |
| Amgen INC. | $108.77 | 2019 | |
| Indivior INC. | $99.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.31 | 2019 | |
| Glaxosmithkline, LLC. | $59.40 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $46.06 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $41.77 | 2023 | Watchman Flx |
| Eisai INC. | $36.79 | 2020 | |
| Abbott Laboratories | $22.12 | 2022 | |
| Corium, LLC | $21.64 | 2023 | Azstarys |
| Medtronic, INC. | $17.35 | 2021 | |
| Amarin Pharma, INC. | $14.99 | 2020 | |
| Abbvie INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Albanese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.